Enterin is aiming to become the first company
in the world to develop a novel drug that
repairs the dysfunctional
in patients with neurodegenerative disease.
In preclinical model of Parkinson’s Disease,
our lead compound displaces α-synuclein aggregates
and restores normal signaling between the gut and the brain.
In early 2017,
our lead compound (ENT-01) will be the
first drug targeting
the gut-brain axis
to move into human clinical trials.
We hope that repair of the gut-brain axis is able to
quality of life
by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.
Leadership & Founders
Board of Directors
Scientific Advisory Board